BMS, Enterome in microbiome immuno-oncology deal

Bristol-Myers Squibb Co. (NYSE:BMY) and Enterome Bioscience S.A. (Paris, France) partnered to discover and develop microbiome-associated biomarkers, targets, therapeutic molecules and companion diagnostics to treat cancer. The partners also hope to identify biomarkers associated with BMS's immuno-oncology portfolio.

The companies will use Enterome's metagenomic technology, which includes fecal bacterial genetic sequencing and mapping technology intended to characterize personal disease phenotypes, and genomic or metagenomic screening technology for target and drug discovery...